Clinical Trials Update from NCI, June 2019

National Cancer Institute banner

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

 
Clinical Trials
Updates from the National Cancer Institute
 
Clinical Trials News
 
Pancreatic tumor illustration  

Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer


Olaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.

 
Androgen receptor illustration  

More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer


In two large clinical trials, the drugs enzalutamide (Xtandi) and apalutamide (Erleada), respectively, combined with androgen deprivation therapy, improved the survival of men with metastatic prostate cancer that still responds to hormone-suppressing therapies.
 
BCL2 clip  

Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia


The Food and Drug Administration has approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The new approval is based on results from a phase 3 clinical trial.

 
Image of smoldering myeloma cells  

Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer


The drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from an NCI-supported clinical trial.
 
Illustration of T-DM1 mechanism of action  

T-DM1 Approval Expanded to Include Early-Stage HER2-Positive Breast Cancer


FDA has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla), also called T-DM1, to include adjuvant treatment in some women with early-stage HER2-positive breast cancer based on findings from a large clinical trial.

 
 
Clinical Trials Information for Patients and Caregivers
 

Insurance Coverage and Clinical Trials


Although the experimental treatment given in clinical trials is often free, participants are usually required to pay usual care costs. This page discusses what clinical trial costs health insurance plans are required to cover, what conditions must be met for insurance to cover these cost, and what costs plans may not cover.

 

Federal Government Programs


Some federal programs may help pay the costs of care in clinical trials for eligible beneficiaries. This page describes those programs and who they can help.

 
Find NCI-Supported Clinical Trials
Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
 
 
NCI-Supported Clinical Trials That Are Recruiting Patients 
 

Basket Trial Seeks to Improve Understanding of ALK-positive Lung Cancer


This phase 2 trial is testing several different drugs and biomarkers in patients with late-stage, ALK-positive non-small cell lung cancer whose tumors are resistant to previous ALK inhibitor therapy. Doctors will assess the overall response rates in patients in the trial’s nine treatment groups.

 

Testing Different Conditioning Therapies Before Stem-Cell Transplant


This phase 2 trial will test a new method for blood-forming stem cell transplantation from healthy donors to patients with a rare type of lymphoma. Patients with relapsed or resistant peripheral T-cell lymphoma will undergo either reduced-intensity conditioning therapy or immunosuppression only prior to transplantation with donated blood or bone marrow stem cells.

 

Combination Therapy for Recurrent Head-and-Neck Cancer


This phase 1 trial is testing the drug birinapant combined with intensity-modulated radiation therapy (IMRT) for patients with head-and-neck squamous cell carcinoma that has recurred after treatment with chemoradiotherapy. Researchers want to assess the side effects and determine the best dose of birinapant when combined with IMRT for future clinical trials.